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Abstract
Allogeneic hematopoietic stem cell transplantation represents the only poten-
tially curative therapeutic approach for Acute Myeloid Leukemia. The choice to
perform an allogeneic hematopoietic transplant is the result of a decision-making
process that considers disease-related factors (AML-risk category and the state of
disease at the time of transplant), the type of donor available and his characteristics
(HLA compatibility, gender, CMV serostatus) and the individual risk associated
with the procedure itself. The choice of the appropriate conditioning regimen
depends on the patient’s age and comorbidities. While the introduction of reduced
intensity regimen and the availability of alternative donors allows more patients to
be eligible for transplantation, myeloablative conditioning remains the standard of
care for fit patients. Disease relapse is the leading cause of treatment failure and
new strategies attempting at reducing the relapse incidence post transplantation are
currently being investigated.
Keywords: acute myeloid leukemia, allogeneic stem cell transplantation,
treatment-related mortality, donor selection, conditioning regimen
1. Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only
potentially curative therapeutic approach for Acute-Myeloid Leukemias (AML) [1].
This approach is often limited by the patient’s transplant-eligibility, which depends
on age and comorbidities. Moreover, in patients considered at low risk of relapse,
allogeneic transplantation can be offered in case of disease relapse rather than in
first complete remission. The high percentage of relapse of leukemia is the leading
cause for failure of transplant [2]. The outcome of patients who relapse after
transplantation is poor, especially for those who relapse within six months after
transplantation for which overall survival at two years is often inferior to 20% [3].
Allogeneic HSCT for AML in first CR is indicated, according to The European
Leukemia Network (ELN), when the risk of relapse exceeds 30–40% and the advan-
tage in disease-free survival (DFS) that can derive from it is greater than 10% [4].
The choice to perform an allogeneic hematopoietic transplant is the result of a
decision-making process that considers the AML-risk category together with the
transplant risk calculated by evaluating both age and comorbidities. In adjunct, the
decision-making process comprises the assessment of the disease-status at the
moment in which the patient comes to the observation of the transplant-physician.
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For patients in complete remission of the disease, also, the status of minimal resid-
ual disease must be considered [5] so that the most appropriate conditioning regi-
men and modulation of immunosuppressive therapy post-transplant can be chosen.
2. Indications to allogeneic transplantation for acute myeloid leukemia
2.1 AML-risk categories
2.1.1 Low risk, intermediate risk AML and the role of minimal residual disease (MRD)
The European Leukemia Network (ELN) has recently redefined the risk catego-
ries for AML into three risk-groups: favourable, intermediate and adverse according
to karyotype and somatic mutations harboring prognostic significance (Table 1)
[6]. The EBMT has provided guidance on indications for transplantation based on
clinical evidence and current practice which was updated in 2019 [7]. According to
EBMT indications for transplant-eligible patients with favorable risk in first com-
plete remission, the autologous stem cell transplantation may be an option instead
of repeated consolidation cycles if MRD is negative. Allogeneic HSCT (from HLA-
identical sibling or unrelated donor) remains an option in case of MRD positivity. A
growing body of evidence indicates that the pre-transplant evaluation of minimal
residual disease (MRD) has a prognostic significance [8–10] and it hasto be consid-
ered for the transplant choice. Pre-transplantation positivity of MRD is associated
with worse overall survival, disease free-survival and relapse incidence [10]. For
Intermediate-risk patients in 1st CR allogeneic transplant from an HLA identical
sibling is considered as “standard”while autologous transplantation and HSCT from
unrelated-donor and alternative donor are considered clinical options [7]. Mannis
et al. retrospectively analyzed data from 334 consecutive adult AML patients who
underwent to autologous transplantation between 1988 and 2013. Among these
patients, 133 were classified as intermediate-risk according to karyotype. Median
relapse-free survival (RFS) was three years and 45% of patients maintain a com-
plete remission at five years. Fifty-four patients relapsed after auto-SCT and of
whom 26 underwent to allo-HSCT. Among allografted patients 35% (9/26) died of




Favourable t(8;21)(q22;q22.1); RUNX1-RUNX1T1 inv.(16)(p13.1q22) or t(16;16)(p13.1;q22);
CBFB-MYH11; Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow; Biallelic
mutated CEBPA.
Intermediate Mutated NPM1 and FLT3-ITDhigh; Wild-type NPM1 without FLT3-ITD or with FLT3-
ITDlow (without adverse-risk genetic lesions); t(9;11)(p21.3;q23.3); MLLT3-KMT2A;
Cytogenetic abnormalities not classified as favorable or adverse.
Adverse t(6;9)(p23;q34.1); DEK-NUP214 t(v;11q23.3); KMT2A rearranged t(9;22)(q34.1;q11.2);
BCR-ABL1 inv.(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1) 25 or del
(5q); 27; 217/abn(17p) Complex karyotype, monosomal karyotype;






ELN Risk stratification by genetics.
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follow-up of 3.8 years while the remaining five patients lost at follow-up. The
authors conclude that ASCT in 1st CR may cure about 40% of patients affected by
intermediate-risk AML. However, the study of Mannis et al. is limited by the
absence of mutational testing for FLT3-ITD and NPM1 end CEBPA for the vast
majority of patients and the risk stratification is based on cytogenetics only [11].
National Comprehensive Cancer Network (NCCN) guidelines do not recommend
ASCT as a treatment option for intermediate-risk AML in 1st CR outside of a clinical
trial [12]. The recent GIMEMA AML 1310 study evaluated a risk-oriented treatment
in intermediate-risk (IR) patients in 1st CR: the patients underwent to autologous or
to allogeneic transplantation according to post-consolidation negative or positive
MRD respectively [13]. Overall survival (OS) and disease-free survival (DFS) in
intermediate-risk MRD-positive patients who underwent to allo-HSCT were com-
parable to OS and DFS of favourable-risk (FR) patients that underwent to autolo-
gous transplantation (IR-MRD+: OS and DFS 70% and 67% respectively – FR: OS
and DFS 74% and 61% respectively). In IR-MRD negative patients who underwent
to autologous stem cells transplantation (ASCT) OS and DFS were 79% and 61%
respectively [13]. MRD was evaluated by detecting Leukemia-associated phenotype
(LAIP) by 8-colour multiparametric flow cytometry and the threshold was 3.5 x
10e-4 leukemic cells.
Based on the GIMEMA AML 1310 trial, the transplant choice in transplant-
eligible intermediate-risk AML patients in 1st CR should be taken according to post-
consolidation MRD. Some difficulties limit the application of MRD in clinical prac-
tice: the cut-off levels, the absence of LAIP or genetic mutations evaluable as MRD-
markers in a portion of AML-patients, experience of the laboratory, the method
used for molecular MRD assessment. As regard to cut off levels, a consensus from
the ELN recommends 0,1% as the threshold level for MRD-positivity [14]. Some
studies indicate that also MRD levels inferior to 0.1% are consistent with MRD
[15, 16], although residual leukemic cells between 0.01% and 0.1% may define a
good-prognosis sub-group of patients. Further studies are needed to address the
prognostic significance of very low levels of MRD. As regards to the method used
for molecular MRD assessment, the ELN consensus recommends real-time quanti-
tative PCR (RQ-PCR) as the standard. RQ-PCR can detect up to 0.1% residual
leukemic cells, although further improvements will come from more advanced
approaches based on techniques not yet validated such as next-generation sequenc-
ing (NGS) and digital-PCR. Validated markers for MRD are RUNX1-RUNX1T1,
CBF-B/MYH11, PML-RARα, NPM1-mutation. About 60% of AML-patients lacks a
somatic mutation suitable for MRD monitoring and WT1is not recommended as a
marker for MRD [14]. Mutations interesting DNMT3A,TET2 and ASXL1 loci may
persist in CR without having a defined prognostic significance in terms of increased
risk of relapse [17].
2.1.2 High-risk AML
The categories comprising high-risk acute myeloid leukaemias (i.e. AML har-
boring FLT3-ITD, monosomic karyotype or complex karyotype, abn(17p), 5q- or
del(5), 7q- or del(7), inv.(3) or t(3;3), t(8;9), t(8;22), AML harboring mutated
RUNX1, ASXL1,TP53, secondary and therapy-related AML) have a poor prognosis
in the absence of allogeneic hematopoietic transplantation.
As regard to FLT3-mutated-AML, the mitigating effect of NPM-1 mutation on
outcome has been established [18, 19]. ELN has distinguished between two catego-
ries: AML harboring NPM1-mutated and FLT3-ITD at high allelic ratio or FLT3-ITD
at low allelic ratio and wild-type NPM1 are classified into intermediate-risk AML
while AML harboring FLT3-ITD at high allelic ratio and wild-type NPM1 are
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classified as high-risk AML [6]. Given the high risk of relapse, a recent position-
statement by the EBMT recommends allo-HSCT for FLT3-mutated AML (also with
NPM1-mutation) in 1st CR from related or alternative donors. The expert panel also
recommends a maintenance treatment with FLT3-inhibitor: Sorafenib is the
suggested option if the patient is treated outside of a clinical trial [19, 20].
As regards the high-risk categories harboring a particular adverse prognosis
AML expressing del(5)/5q-, del(7)/7q-, abn(17p), monosomic karyotype, the EBMT
have conducted a retrospective analysis on transplant outcome reporting two-year
overall survival and leukaemia-free survival between 27% and 34% and between
20% and 24% respectively [21–23]. The worse outcome was observed in patients
expressing both 5q- and abn(17p) [23].
2.1.3 Secondary- and therapy-related AML
Secondary AML (sAML) and therapy-related AML comprise a group of hetero-
geneous disease that, respect to de novo AML, occur more frequently in elderly
patients, most often are chemo-resistant to cytotoxic chemotherapy and have a
worse prognosis [24]. Sengsayadeth et al. have conducted a retrospective analysis
on 3960 patients affected by sAML undergoing to allo-HSCT between 2000 and
2016. The two years overall survival and disease-free survival were respectively
45% and 39%. The subgroup of patients receiving HSCT not in complete remission
experienced the worse outcome (2 years OS and DFS, respectively 35 and 29%) [25].
Recently the Acute Leukemia Working Party of the EBMT published a retrospective
registry-based study comparing the outcome of allo-HSCT for sAML and de novo
AML patients transplanted in the time interval 2000–2016. The three years overall
survival, disease-free survival and cumulative incidence of relapse (CIR) were
respectively 60%, 55%, 28% and 46%, 41% and 35% respectively for de novo AML
and sAML. In multivariate analysis, sAML was associated with worse OS, DFS and
CIR than de novo AML [26]. In patients fit for transplant affected by sAMLallo-
HSCT must be offered upfront, preferably in 1st CR. Novel agent CPX351 (liposo-
mal formulation of Cytarabine and Daunorubicine in a 5:1 ratio) has been recently
approved as induction treatment for these patients and has demonstrated superior-
ity compared to the conventional “7 + 3” schedule [27].
2.1.4 Chemotherapy-refractory AML
The prognosis of patients who fail to reach complete remission after induction
chemotherapy is poor. In these patients, five years survival is <10%. Allogeneic
transplantation may improve survival to 25–30% [28].
Jabbour et al. compared outcomes of 28 AML primary-induction failure (PIF)
patients who underwent to allo-HSCT to that of 149 PIF patients who were treated
with salvage chemotherapy alone: results were dramatically in favour of allo-HSCT
with a three years OS rate of 39% for allo-grafted patients versus 2% for
chemotherapy-only patients [29].
Ferguson et al. in a retrospective analysis on 8907 patients have found that
patients who fail to achieve a reduction of myeloid blasts <50% with >15% residual
blasts after one course of induction chemotherapy as well as patients who fail to
achieve complete remission after two courses of induction chemotherapy have a
very dismal prognosis if treated with further chemotherapy. Allogeneic stem cell
transplantation may improve survival of these patients [28].
The FLAMSA regimen has been designed for patients with active disease who
undergo allo-HSCT. It comprises an initial debulk with Aracytin, Fludarabine
and Amsacrine followed by a reduced-intensity conditioning and HSCT [30, 31].
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In summary, allogeneic HSCT may rescue about 30% of patients with primary
induction or re-induction failure and the improvements in recent years in HLA-
typing, donor availability (i.e. haploidentical donors), conditioning regimen and sup-
portive care expand the possibility to give allogeneic transplantation to this category
of patients [32]. In primary refractory disease performing more than two induction
courses before allogeneic transplantation has no benefit [28, 30]. Duval et al. devel-
oped a prognostic score for the outcome of allo-HSCT performed for AML refractory
to chemotherapy (named Duval Score). They analyzed data from 1673 patients from
CIBMTR registry and developed a score based on five variables: phase of disease at
HSCT (PIF or refractory relapse after CR > 6 months versus refractory relapse after
CR < 6 months), cytogenetic class of risk (good/intermediate vs. high), circulating
blasts (absent vs. present), HLA match (HLA matched related vs. matched unrelated
vs. mismatched unrelated vs. haploidentical) and Karnofsky Score (KS: > 90 vs.
< 90). Four class of risk correlated with different survival were identified. Three-
years OS varied from 40% for score 0 versus 6% for score ≥ 3 [33].
2.1.5 Transplantation in 2nd CR
The current indications for allo-HSCT in 2nd CR include transplantation-eligible
patients affected by low-risk AML relapsed after previous chemotherapy or autolo-
gous transplantation [7]. Allo-HSCT in 2nd CR may also be offered to patients for
whom this procedure was previously considered not indicated or too risky (for
example intermediate-risk AML for whom MRD was absent after consolidation
chemotherapy, or patients lacking HLA-identical sibling donors and considered
unfit for an alternative donor at the time of 1st CR).
Some retrospective analysis by ALWP of EBMT has addressed the role of allo-
geneic transplantation in 2nd CR of AML. Christopeit and coll. have analyzed 537
patients who have undergone allograft in 2nd CR or first relapse after ASCT: 3-years
overall survival (OS), leukaemia-free survival (LFS) and non-relapse mortality
(NRM) were respectively 39.5%, 31.5% and 33%. Cumulative incidence of relapse
(CIR) was 34.6%. A longer survival correlated with allo-HSCT performed in com-
plete remission than in chemo-refractory relapse, with favorable-risk cytogenetics
and with a longer duration of 1st CR (more than ten months in median).NRM was
higher in patients undergoing to allo—HSCT from alternative donors than HLA-
identical sibling and in those who received Total-body Irradiation (TBI) as part of
the conditioning pre-ASCT [34].
Gilleece and coll. published a registry report by the EBMT on allo-HSCT in 2nd CR
of AML including 1879 patients transplanted between 2007 and 2016. The global
outcome at 2 years were: LFS: 52%, OS: 58%, Relapse Incidence: 30%. NRM was 20%.
The results were split by age < 50 or ≥ 50 years old and by the intensity of condi-
tioning. OS and LFS for <50 yrs. old were 61% and 54% respectively (without
differences due to conditioning regimen). For ≥50 years old OS was respectively 58%
and 54% for myeloablative (MAC) and reduced-intensity conditioning (RIC) and LFS
was 50% for both conditioning regimens. In multivariate analysis, the intensity of the
conditioning regimen did have an impact on NRM that was lower for RIC in patients
aged ≥50 years (HR 0.54, p < 0.001). Overall Survival, LFS, CIR and Graft-relapse
free survival (GRFS) were better in patients with longer intervals from diagnosis to
allo-HSCT. Performance status (PS) and the cytogenetic class of risk at diagnosis
(good, intermediate and adverse) also correlated with outcome [35].
Halaburda K et al. retrospectively analyzed 631 patients affected by Core-
binding factor (CBF) AML who were allo-grafted in 2nd CR and reported to the
EBMT registry between 2000 and 2014. Five-years OS and LFS were respectively
58% and 54% while relapse and NRM at were 22.5% and 23%. The composite
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end-point of Graft-relapse free survival (GRFS) at 2 and 5 years was 40 and 34%
respectively. In multivariate analysis, GRFS was associated with three or more
additional cytogenetic abnormalities and in vivo T-cell depletion (HR 1.6, P = 0.03).
A trend for a better GRFS was associated with a transplant from a CMV-
seronegative donor and for MRD –negative status at allo-HSCT [36].
Passweg and coll. conducted a retrospective study to compare the impact of a
previous ASCT versus chemotherapy consolidation without ASCT on the outcome
of allo-HSCT performed in 2nd CR. The study included 2619 allo-grafted patients in
2nd CR between 2000 and 2017. Of these, 417 were previously treated in 1st CR
with ASCT and 2202 with chemotherapy consolidation respectively. The patients
were not evenly distributed among the two cohorts because patients treated with
ASCT respect to those treated with chemotherapy consolidation were younger, had
undergone transplantation earlier, had more often an unfavorable karyotype, more
often received allo-HSCT from alternative donors than from HLA matched siblings
and more often received a RIC than a MAC regimen. Two-years OS, LFS, GRFS and
NRM were respectively 58, 50, and 21% for chemotherapy consolidations and 55,
46, 35 and 25% for ASCT-patients. In multivariate analysis risk of NRM, LFS and
GRFS were higher for previous ASCT-patients than for previous chemotherapy
consolidation patients. As well as in the study of Christopeit NRM of the allogeneic
transplant was higher for patients in whom TBI was included in the pre-ASCT
conditioning [37]. However, after first relapse, the attempt of a second complete
remission is not always successful and if outcome is measured from the time-point
of relapse, the overall results are very poor. Infact, only 10% of all AML patients
that relapse and are treated with re-induction chemotherapy and subsequently with
allogeneic hematopoietic transplantation are survivors at 5 years [38].
In summary, about 50% of patients in 2nd CR of AML, if eligible to transplanta-
tion, may be rescued by allo-graft, particularly when 1st CR has been longer than six
months [33]. The chance to achieve a second remission after a first relapse is,
however, limited. Furthermore, prior autologous transplantation is associated with
an increased risk of NRM post allogeneic transplantation and this must be consid-
ered when choosing auto-transplantation in 1st CR, in particular for low and
intermediate-risk AML.
3. Risk assessment
Allogeneic Hematopoietic Stem Cell Transplantation remains a procedure asso-
ciated with significant mortality and morbidity.
Once the bone marrow transplant has been established as a therapeutic indica-
tion, the candidate has to be evaluated in order to define eligibility for treatment
and to choose the most appropriate conditioning regimen.
The study of the factors related to the disease, to the donor characteristics and to
the patient’s general health allows us to evaluate the probability of post-HSCT non-
relapse mortality (NRM).
Here we describe the predictive models used in the clinical practice that quantify
the post-HSCT risk profile by integrating all these different factors and therefore
predict tolerability to allogeneic BM transplant.
3.1 Disease risk index (DRI)
The score arises from the evidence that the outcome of HCT depends on the
state of the disease at the time of transplantation. Armand et al. led to the
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development of the Disease Risk Index, conducting a retrospective study involving
1539 patients analyzing information about the disease and its status [39].
It does not take into account factors like age and comorbidities. It categorizes
patients into four risk groups with different OS and PFS based on differences in the
relapse risk as described in Tables 2 and 3.
3.2 HSCT-Comorbidity Index (HCT-CI)
Sorror et al., through a retrospective analysis study, developed the Hematopoi-
etic cell transplantation-specific comorbidity index (HCT-CI) (Table 4) [40]. Ini-
tially developed in 2005, as an adaptation of the Charlson Comorbidity Index to
HSCT, it was revised in 2014 to include the age variable [41]. Compared to the
previous scores, the HCT-CI places much emphasis on the patient’s general health
and organ dysfunctions, analyzing 17 comorbidities as described in Table 2. It
defines 3 risk groups: score 0 (low risk), score 1–2 (intermediate risk), >= 3 (high
risk).HSCT-CI was subsequently validated in an independent cohort of patients by
Raimondi et al. in 2012 [42]. It is an independent predictor of both NRM and OS.
2 years NRM is 14.7%, 21.3%, and 27.3% in patients having ad HSCT score of 0, 1–2
and > 3 respectively and OS was 56.4%, 21.3% and 41.3% respectively. Patients with
low scores should be enrolled in randomized clinical trials or undergoing high
intensity conditioning regimens (total busulfan dose>8 mg / kg, or cyclophospha-
mide dose>120 mg / kg or > 60 mg/kg in combination with other drugs, or mel-
phalan dose>140 mg/mq or total body irradiation dose>6 Gy), while patients with a
high score should be candidates for the reduced intensity/non myeloablative condi-
tioning regimens.
3.3 EBMT score
Another score widely used in transplantation practice is the EBMT risk score
[43]. It was introduced more than ten years ago initially for patients with chronic
myeloid leukaemia (CML), the most frequent indication for allogeneic stem cell
transplantation in those years, and subsequently extended to other haematological
diseases. Each of the five factors taken into consideration has the same “weight” and
importance on the global risk: age, stage of the disease, time from diagnosis, donor
type and donor-recipient gender. The score allows us to predict approximately the
5-year probability of OS and TRM for any disease. The novelty, compared to the
HSCT-CI, is the introduction of the concept of the disease stage to improve the
score predictivity.
1.By age, 3 categories are identified: <20 years (0 score points), 20–40 years
(1 score point) and > 40 years (2 score points). The introduction of low-
intensity conditioning regimes has opened access to allogeneic transplantation
also to elderly patients, but this does not take away the fact that mortality is
higher in this category of patients.
2.For disease stage, three categories are defined: early disease stage (0 score
point) represented by acute leukaemia in first CR, intermediate disease stage
(1 score point) in which acute leukaemia in second CR and late-stage disease
(2 score points) are included with advanced leukaemia.
3.The time interval from diagnosis to transplant provides a cut-off of 12 months.
If the elapsed time is <12 months 0 score points if>12 months one score point.
For acute leukaemias in the first CR we arbitrarily set as 0.
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Disease Disease risk

















1st Complete Remission Low




2nd or subsequent PR (if RIC)
2nd or subsequent PR (if MAC) High
Induction Failure
Active Relapse
Accelerated or Blast Phase CML
Overall assignment






High High Very high
DLBCL, diffuse large B cell lymphoma; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; other
abbreviations are as in Table 1.
Ref. [39].
Table 2.
Summary of disease and stage risk groups from original DRI.
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Hodgkin lymphoma CR 126 0.36 Int 14 Low 66 63–68
CLL CR 81 0.47 Low Low
Mantle cell lymphoma
CR
160 0.51 Int Low
Indolent NHL CR 183 0.53 Low Low
AML favorable
cytogenetics CR
190 0.64 Low Low
Indolent NHL PR 276 0.71 Low Low
CLL PR 400 0.78 Low Low
CML chronic phase 1/2 390 0.82 Low Low
CML advanced phase 69 0.92 Int 63 Int 51 50–52
Mantle cell lymphoma
PR
149 0.95 Int Int
Myeloproliferative
neoplasm
Any 426 0.98 Int Int
AML intermediate
cytogenetics CR
3611 Ref Int Int
ALL CR1 1023 1.00 Int Int
T-cell NHL CR 171 1.00 Int Int
Multiple myeloma CR/
VGPR/PR
339 1.03 Int Int
Aggressive NHL CR 181 1.05 Int Int
Low-risk MDS adverse
cytogenetics
Early† 103 1.06 High Int




Early† 516 1.09 Int Int




Advanced† 235 1.18 Int Int
Indolent NHL Advanced† 128 1.21 Int Int




Early 364 1.24 Int Int
Aggressive NHL PR 205 1.26 Int Int
T-cell NHL Advanced† 93 1.41 High 20 High 33 31–35
AML favorable
cytogenetics
Advanced† 34 1.42 Int High
HL Advanced† 85 1.48 High High
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4.Concerning the type of donor, the identical sibling donors will have a 0 point
score, while the unrelated ones will have one score point. It is interesting to
note how the impact of donor typer is different for different pathologies,
having a significant impact on aplastic anaemia and the least of all for acute
lymphoblastic leukaemia.
5.Last but not least, the gender difference between recipient and donor. Female
donor for male recipient (1 score point) as it has been noted that it leads to a
higher NRM, due to increased incidence of acute and chronic GVHD.
Also donor or recipient cytomegalovirus (CMV) seropositivity has a prognostic
impact: recently a study showed that, compared to CMV-seronegative recipients who

















Advanced† 179 1.56 Int High
High-risk MDS adverse
cytogenetics
Early 80 1.58 High High
ALL CR2 407 1.58 Int High
AML adverse
cytogenetics CR
175 1.59 High High
Mantle cell lymphoma Advanced† 46 1.59 High High
High-risk MDS adverse
cytogenetics
Advanced† 30 1.59 Very
high
High
BL‡ CR 23 1.65 NA High
Multiple myeloma Advanced† 150 1.65 High High
ALL CR3 61 1.70 Int High
Low-risk MDS adverse
cytogenetics





Advanced 1227 1.89 High High
CML blast phase 52 2.02 Int 4 Very
high
23 20–27
ALL Advanced† 235 2.23 High Very
high








BL‡ PR Advanced† 12 5.21 NA Very
high
Int, intermediate. Ref. [39].
*Hazard ratio for mortality compared with AML intermediate cytogenetics in CR1.
†Advanced stage refers to induction failure or active relapse, including stable or progressive disease for NHL, HL, and CLL.





underwent allograft from a CMV-seronegative donor, cases of CMV seropositivity of
the donor and/or the recipient showed a significantly decreased 2-year leukemia-free
survival (44% vs. 49%, P < .001) and overall survival (50% vs. 56%, P < .001), and
increased nonrelapse mortality (23% vs. 20%, P < .001) [44]. In a CIBMTR analysis
early CMV-reactivation was associated with lower overall survival (HR: 1.27) and it
was confirmed as a poor risk factor for post-transplant outcome [45].
Also cytokine’s encoding gene polymorphisms seem to have a prognostic impact.
It has been shown that single nucleotide polymorphisms (SNPs) in the IL-6
encoding gene influence outcome after allogeneic stem cell transplantation as
described by Tvedt et al. [46].
4. Donor selection
The selection of a donor is a critical element contributing to the success of
hematopoietic cell transplantation (HCT).
Among the many factors that influence the outcome of hematopoietic stem cell
transplantation, polymorphism of the classical human leukocyte antigen represents
the most important barrier [47]. The human Major Histocompatibility Antigens is
located on the short arm of chromosome 6. The MHC falls into three main regions,
class I, II and III. The most relevant genes for transplantation belong to class I
(HLA-A,HLA-B and HLA-C) and class II (HLA-DR,HLA-DQ andHLA-DP). MCH
genes are inheritedin a co-dominant manner following Mendelian rules. Therefore,
Comorbidity HCT-CI score N %
Arrhytmia 1 7 3
Cardiac 1 18 9
Inflammatory bowel disease 1 1 0.5
Diabetes 1 5 2
Cerebrovascular disease 1 1 0.5
Psychiatric disturbance 1 10 5
Hepatic-mild 1 10 5
Obesity 1 14 7
Infection 1 28 14
Rheumatologic 2 2 1
Peptic ulcer 2 2 1
Moderate/severe renal 2 8 4
Moderate pulmonary 2 30 15
Prior solid malignancy 3 12 6
Heart valve disease 3 4 2
Severe pulmonary 3 49 24
Moderate/severe hepatic 3 2 1
No comorbidities 0 65 32
Abbreviation: HCT-CI, hematopoietic cell transplantation comorbidity index; N, number of patients. Ref. [40].
Table 4.
Definitions of comorbidities included in the HCT-CI score.
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the probability for siblings to be HLA-identicalis 25% [48]. HLA compatibility with
the donor is usually defined by high-resolution typing (four digits) for ten alleles,
HLA-A, HLA-B, HLA-C, HLA-DR and HLA-DQ , but there is increasing evidence
supporting the relevance of DPB1matching [49]. An HLA–identical sibling donor is
generally considered the best donor for allo-HSCT; however, less than a third of
patients will have one available. For the remaining 70% of patients, alternative
sources of stem cells are a matched unrelated adult volunteer donor, a
haploidentical donor or a cord blood unit. The probability of identifying a highly
matched unrelated donor depends on the frequency of the patient’s HLA haplotypes
and ethnic origin. 1–5% of patients do not have a single potentially matched donor
upon direct interrogation of the BMDW database because the large majority of
donors registered in the database are of Western European ancestry. In European
countries, 45–65% of patients will eventually have a 10/10 matched donor, and a 9/10
matched donor may be identified for an additional 20–30% of patients [50].
There is a consensus that single HLA-A, B or C allele mismatches and double HLA-
DRB1 mismatches are associated with increased mortality in non-T-cell-depleted
bone marrow transplantation [51]. Disparities in HLA-DQB1, as well as C-allele
disparities in C 03:03 vs. 03:04, have been reported to be permissive with no adverse
effects on the outcome [52]. Disparities in HLA-DPB1 are observed in the majority of
HLA-A, HLA-B, HLA-C and HLA-DQB1 (10/10) MUD transplants [53]. Different
studies have demonstrated that biological models can be used to identify selected,
permissive DPB1mismatches combination, associated with lower clinical risks com-
pared to their high risk, non-permissive, counterparts. There are five different bio-
logical models for the assignment ofDPB1 permissiveness that have been identified to
date, three of which are based on functional T-cell epitopes (TCE) [54]. A study
shows that survival probabilities can be significantly increased by selecting donors
with TCE4- permissive HLA-DPB1 disparities, with a significant association with
NRM and OS in 10/10 and 9/10 matched transplantation. Therefore, the UD searches
should be directed up-front toward the identification of a 10/10 or 9/10 matched
donor presenting TCE4-permissive HLA-DPB1 disparities [55].
Whenever two or more 10/10 matched donors are available, other factors are
studied. We have to evaluate the presence of HLA-antibodies in the recipient and
select a donor for whom there are no recipient donor-specific anti HLA antibodies
(DSA). An essential element is the donor age with priority for the youngest. Another
factor is the matching for patient/recipient CMV serostatus with the best scenario be a
seronegative patient receiving from a seronegative donor. Donor gender is also con-
sidered with priority for the male donor since female donor can immunize post-
pregnancy. Another factor to be considered is AB0-matching, even though the impact
of blood group compatibility on outcome has been reported to be modest [56]. Other
factors to be considered include NK cell alloreactivity and KIR haplotype matching
and non-inherited maternal HLA antigens (NIMA) mismatching [57].
Many advances in MUD HCT have occurred over the past 20 years and several
studies suggest that transplantation from fully Matched Unrelated Donor (8/8 or
10/10) and Matched Sibling Donor results in similar survival times for patients with
AML [58]. The study of Center for International Blood and Marrow Transplant
Research analyzed outcomes of 2223 adult acute myelogenous leukaemia patients
who underwent allogeneic HCT between 2002 and 2006 (HLA-Matched related
donor MRD, n = 624; 8/8 HLA locus matched MUD, n = 1193; 7/8 MUD, n = 406).
The 100-day cumulative incidence of GVHD was significantly lower in MRD HCT
recipients than in 8/8 MUD and 7/8 MUD HCT recipients (33%, 51% and 53%
respectively; P < .001). In multivariate analysis, 8/8 MUD HCT recipients had a
similar survival rate compared with MRD HCT recipients. 7/8 MUD HCT recipients
had higher early mortality than MRD HCT recipients, but beyond six months after
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HCT, their survival rates were similar [58].Another study compared the outcomes
of the unrelated donor (URD, n = 385) with human leukocyte antigen (HLA)-
matched sibling donor (MSD, n = 226) transplantation in patients with acute mye-
loid leukaemia in first complete remission (CR1) having unfavourable cytogenetics
at diagnosis. Three-year leukaemia-free survival (LFS) for MSD was 42% compared
with 34% for HLA-well-matched URD and 29% for partially matched URD. In
multivariate analysis, HLA-well-matched URD and MSD yielded similar LFS and
OS. LFS and OS were significantly inferior for HLA-partially matched URD recipi-
ents, those with prior myelodysplastic syndrome, and those older than 50 years.
Patients with chronic GVHD had a significantly lower risk of relapse [59].
If 10/10 matched unrelated donor is not available, an alternative donor has to be
considered: HLA 9/10 matched unrelated donor; haploidentical donor; HLA
mismatched unrelated donor; cord blood unit.
A haploidentical related donor is defined by the sharing of one haplotype (or a
single identical copy of chromosome 6) with the patient containing the HLA region
involving class I and class II histocompatibility genes (patient’s parents or sons;
sometimes brothers or sisters or cousins). A significant advantage of haploidentical
transplantation is the rapid access to a donor which is of crucial importance for
patients with high-risk AML since a delay in transplantation due to the donor issues
can result in a poor outcome. Today primary prevention and treatment of GVHD
have been a major challenge in this peculiar HLA-mismatched setting [60]. Two
main platforms have been developed: ex vivo T cell depletion, which is used in a
few centers because it is expensive and it needs highly specialized laboratories
[61, 62], and unmanipulated graft transplantation, which is way more used since
the introduction of Post-transplant Cyclophosphamide (PT-CY) (that will be
discussed in the chapter on conditioning regimens). Several studies found that the
OS secondary outcomes of patients with AML who received haplo-HSCT were not
significantly different from MSD-HSCT and MUD-HSCT [63].
Another alternative source of stem cells is the cord blood unit (UCB). It has been
established that a single UCB unit contains sufficient numbers of HSCs for durable
engraftment in most patients.
Thanks to immunological immaturity, an advantage of UCB is its apparent
reduced alloreactive response as compared with bone marrow. The data would
suggest that UCB, despite HLA mismatching, is associated with low GVHD risk.
Disadvantages of Umbilical Cord Blood Transplantation are slower engraftment,
higher risk of non-immunological rejection (graft failure), remote possibility of
transmission of a genetic disease, more significant delay in immune reconstitution,
no possibility of donor lymphocyte infusion [64, 65].
A retrospective analysis including 106,188 adult patients with haematological
malignancies who underwent allogeneic hematopoietic stem cell transplantation
studied overall survival at three years. The results showed: 54.6% for a matched
sibling, 51.6% for a matched unrelated donor, 41.3% for a mismatched unrelated
donor, 44.2% for haploidentical and 43.7% for cord blood [66]. OS following HSCT
is improving with substantial progress among recipients of haploidentical and cord
blood HSCT, but the traditional donor hierarchy of matched sibling donors followed
by matched unrelated donors and then other donors hold [66].
5. Conditioning regimens
Conditioning is the treatment used to prepare patients undergoing hematopoi-
etic bone marrow transplantation. The role of conditioning is to eradicate the
residual haematological disease from the bone marrow, to provide room in the host
13
Stem Cell Transplantation in Acute Myeloid Laeukemia
DOI: http://dx.doi.org/10.5772/intechopen.94416
bone marrow for the donor stem cells and to have an immunosuppressive effect in
order to ensure engraftment.
Conditioning regimens can include Total Body Irradiation (TBI) or they can be
radiation-free and be based only on chemotherapy. They usually consist of a
myeloablative compound (such as Busulfan or Melphalan) and an immunosuppres-
sive agent (such as Fludarabine or Cyclophosphamide).
Conditioning regimens have been classified into three categories based on the
duration of the induced pancytopenia and the requirement for stem cells
support [67]:
Myeloablative conditioning (MAC): a combination of agents expected to produce
irreversible pancytopenia; stem cells support is required to rescue marrow function;
Non-myeloablative conditioning (NMA): a regimen that will cause minimal
cytopenia and does not require stem cells support;
Reduced-intensity conditioning (RIC): a regimen that cannot be classified as
NMA or MA; it can cause pancytopenia which may be prolonged and do require stem
cells support; cytopenia may not be irreversible; RIC regimens differ from MA condition-
ing because of the dose that must be reduced by at least 30%.
Traditionally, the two most important myeloablative regimens were TBI/Cyclo-
phosphamide (Cy) (TBI 12 Gy, Cy 60 mg/kg  2 days) and BU (Busulfan)/Cy (BU
4 mg/kg  4 days and CY 60 mg/kg  2 days). In AML, different studies showed
the equivalence between these regimens in terms of Leukemia Free Survival (LFS)
and Overall Survival (OS) [68, 69]. Cyclophosphamide is often replaced by
Fludarabine, a purine analogue with antineoplastic and immunosuppressive effect
and a better toxicity profile. The combination BU-FLU (BU 4 mg/kg  4 days and
FLU 40 mg/m2/day for four consecutive days) has been demonstrated to be as
effective as the regimen BU-CY but with a lower Transplant Related Mortality
(TRM) [70, 71]. Thiotepa (TT), an alkylating compound with antineoplastic and
myeloablative activity, can be added to these combinations in order to reduce the
risk of relapse [72].
In the last two decades, the introduction of RIC regimens has revolutionized the
transplant landscape by allowing more patients to be eligible for transplantation.
RIC transplantation relies more on the graft versus leukaemia (GvL) effect than a
cytotoxic action for efficacy. RIC regimens are a good treatment option in older
patients (age > 60 years) or younger patients with comorbidities that are ineligible
for a MAC regimen [73]. These regimens usually combine Fludarabine with an
alkylating agent (like Busulfan or Thiothepa) or TBI in reduced doses. Many studies
in the literature comparing MAC and RIC regimens in AML showed a comparable
survival; even though a higher relapse rate was observed in RIC regimen, it was
balanced by a lower TRM [74–78]. To address this question, a phase III randomized
trial comparing MAC with RIC in patients with acute myeloid leukaemia or
myelodysplastic syndromes was performed. In this study, RIC resulted in lower
TRM but higher relapse rates compared with MAC, with a statistically significant
advantage in LFS with MAC. These data support the use of MAC as the standard of
care for fit patients with acute myeloid leukaemia [79].
Intermediate-intensity conditioning has been developed to reduce the relapse
incidence (RI) while maintaining a reduced TRM after RIC transplantation. The
FLAMSA regimen has been designed for patients with active disease who undergo
allo-HSCT. It comprises an initial debulk with Aracytin, Fludarabine and Amsacrine
followed by a reduced-intensity conditioning and HSCT [80–81]. Schmid and coll.
employed the FLAMSA regimen on 75 consecutive high-risk patients, 27 of whom
affected by primary refractory AML and 22 by untreated relapse of AML, and
reported a one-year non-relapse mortality of 33% and a 2-years DFS of 40%. This
regimen also includes the use of prophylactic donor-leukocyte infusions (pDLI) in
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the absence of Graft-Versus-Host Disease (GVHD). The authors describe a better
survival in patients who experienced a mild chronic GVHD respect to no GVHD or
severe GVHD [82].
The Baltimore group has pioneered Post-transplant Cyclophosphamide (PT-CY)
on day +3 and +4 after the transplant in the contest of haploidentical donor trans-
plantation and it reduces the incidence of GVHD [83–86]. PT-CY prevents GVHD
by killing alloreactive T cells of the donor and host origin with preservation of
regulatory T cells; on the other hand, stem cells are protected by the drug because of
their high level of aldehyde dehydrogenase which converts Cy to a non-toxic
metabolite [87]. Since its advent, the transplant from a haploidentical donor has
become one of the most commonly used alternative donor strategies. In the study
by Ciurea et al. clinical outcomes of patients diagnosed with AML undergoing SCT
from MUD or haploidentical donor with PT-CY were evaluated and overall survival
resulted comparable in two groups with a lower incidence of GVHD in the
haploidentical donor group [85]. The introduction of this strategy allowed even
minor transplant centers to be able to perform haploidentical donor transplantation
by omitting the need for ex vivo T cell depletion, which is an expensive procedure
that requires dedicated laboratories. Because of the success demonstrated at
preventing GVHD in the haploidentical setting, its role is now being also evaluated
in the other settings—Matched unrelated donor, HLA identical donor [86, 88]—and
it might be the strategy allowing calcineurin inhibitors and mTOR inhibitors-free
GvHD prophylaxis [89].
Comparable results at preventing GVHD in the unmanipulated HSCT setting
were obtained with another strategy based on the use of BM cells harvested from
donors primed with low dose G-CSF (4 μg/kg/day) and on the administration of
either MAC or RIC preparative regimen and an intensive GVHD prophylaxis
consisting of a combination of five drugs: ATG, CSA, MTX, MMF and Basiliximab
[90]. G-CSF stimulation increases the number of BM CD34+ cells [91] and has an
intense immunoregulatory effect on BM T cells by down-regulating the expression
of adhesion and CD28/B7 molecules and by favouring a T-cell shift from Th1- to
Th2-type cells and inducing a higher production of IL-4 and IL-10 anti-
inflammatory cytokines [92].
T-cell depletion to prevent GVHD remains an option in the haploidentical set-
ting and the lack of extensive prospective studies comparing it with the
unmanipulated graft transplantation leave the choice to the experience of the SCT
center. This modality has been associated with a higher leukaemia relapse incidence
- since T cells are responsible for the graft versus leukaemia effect - and higher TRM
due to slower engraftment and a higher incidence of opportunistic infections [93].
New methods of graft manipulation have been developed in order to address these
problems. A promising approach is the graft depletion of B cells and T cells carrying
the γδ chains of T cell receptor (TCR), being responsible for GVHD, while keeping
αβ T cells and Natura Killer (NK) cells that play an essential role in anti-tumour
surveillance and the antiviral immunity (TCR γδ/CD19 negative selection) [94]. A
different strategy recently presented by the Perugia group is the infusion of donor
regulatory T cells at day – 4 followed by the infusion of a megadose of CD34+ and
conventional T cells on day 0 and no use of pharmacological post-transplant immu-
nosuppression. This method resulted in a significant reduction in the incidence of
leukaemia relapse, suggesting that regulatory T cells limit GVHD with no loss of
GvL [95].
Disease recurrence remains the leading cause of treatment failure [96]. In order
to reduce the RI post allogeneic stem cell transplantation (allo-SCT), studies
including cellular therapies (DLI) [97, 98] and new drugs that seem to enhance the
GvL effect like FLT-3 inhibitors, immune checkpoint inhibitors [99] and epigenetic
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therapies in the post-transplantation setting are ongoing. In the RICAZA trial
azacitidine was administrated for the first year after transplantation in 51 patients
affected by AML undergoing allogeneic SCT and it showed a reduced risk of disease
relapse [100].
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